Role of FGFR3 in Urothelial Carcinoma

Background and Objective: This study was undertaken to analyze the immunohistochemical expression of fibroblast growth factor receptor (FGFR3) in urothelial carcinoma and correlate its expression with the pathological stage, recurrence and other clinicopathological parameters. Material and Methods:...

Full description

Saved in:
Bibliographic Details
Main Authors: Malik Akanksha (Author), Sundaram Sandhya (Author)
Format: Book
Published: Iranian Society of Pathology, 2019-04-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_b99f4d9037e94225a65af6f9a7e2d2e2
042 |a dc 
100 1 0 |a Malik Akanksha  |e author 
700 1 0 |a Sundaram Sandhya  |e author 
245 0 0 |a Role of FGFR3 in Urothelial Carcinoma 
260 |b Iranian Society of Pathology,   |c 2019-04-01T00:00:00Z. 
500 |a 1735-5303 
500 |a 2345-3656 
500 |a 10.30699/ijp.14.2.148 
520 |a Background and Objective: This study was undertaken to analyze the immunohistochemical expression of fibroblast growth factor receptor (FGFR3) in urothelial carcinoma and correlate its expression with the pathological stage, recurrence and other clinicopathological parameters. Material and Methods: A retrospective study was undertaken on paraffin blocks of 55consecutiveurothelial carcinoma specimens in 28 months received in Sri Ramachandra Medical College, Chennai, India. Blocks with the sections containing the tumor and adjacent normal epithelium were chosen for the immunohistochemical (IHC) study of FGFR3.  Results: IHC expression of FGFR3 in high grade (HG) invasive urothelial carcinoma was positive in 18% cases, 66.7% of HG non-invasive urothelial and 82.6% of low grade (LG) non-invasive urothelial carcinomas. The FGFR3 expression was presented in 78.1% of non-invasive carcinoma. In case of invasive urothelial carcinoma, the FGFR3 positivity was observed in 18.2% of tumors (P<0.05). FGFR3 expression in LG tumors was positive in 82.6 % of the cases whereas 32.3% of HG cases were positive for FGFR3 (P<0.05). FGFR3 was expressed in 14.3 % of HG invasive tumors which recurred. HG non-invasive tumors were positive for FGFR3 in 80% of the cases. LG non-invasive tumors were positive for FGFR3 in 72.7% of cases (P<0.05). Conclusion: The expression of FGFR3 is higher in low grade, non-invasive tumors and recurrent non-invasive tumors. The targeted therapy for FGFR3 may be used as one of the modes of treatment for urothelial carcinoma. It can also be used as a marker to determine the grade in difficult cases and the risk of recurrence. 
546 |a EN 
690 |a fgfr3 
690 |a urothelial carcinoma 
690 |a carcinoma transitional cell 
690 |a bladder cancer 
690 |a Pathology 
690 |a RB1-214 
655 7 |a article  |2 local 
786 0 |n Iranian Journal of Pathology, Vol 14, Iss 2, Pp 148-155 (2019) 
787 0 |n https://ijp.iranpath.org/article_35715_10f0c28f8ade9292f828cfc9327f3e9c.pdf 
787 0 |n https://doaj.org/toc/1735-5303 
787 0 |n https://doaj.org/toc/2345-3656 
856 4 1 |u https://doaj.org/article/b99f4d9037e94225a65af6f9a7e2d2e2  |z Connect to this object online.